Half Life: 6 Days (Plasma), 12 Months (Liver)
Our team has found that for general wellness research or when dealing with multiple injury sites, a systemic protocol is often the preferred starting point due to its safety and ease of use
FDA does not review compounded medications for safety, effectiveness, or quality before they are marketed
Transparent results
Meanwhile, some in the medical community believe the unfettered use of peptides, often guided by a colorful array of YouTubers, represents one of the most dangerous frontiers in medicine today as it leaves the patient to also be the doctor, the nurse, and the pharmacist all in one
FOXO4-DRI vs nearby senolytics Option FOXO4-DRI Type D-retro-inverso peptide Human trial stage None (preclinical only) Option Dasatinib + Quercetin (D+Q) Type Small-molecule drug + flavonoid Human trial stage Early human trials (e.g., Alzheimer's) Option Navitoclax Type BCL-2 family inhibitor Human trial stage Later-stage trials (e.g., myelofibrosis) D+Q and navitoclax are further along in humans but can affect healthy cells (e.g., low platelets)
